This Enrichment seminar covers the discovery of novel kinase inhibitors that mitigate pathological airway remodeling associated with asthma. Dr. Shapiro discusses how ICTR resources helped generate preliminary data and NIH funding through the R61/R33 Catalyze program at the National Heart, Lung, and Blood Institute. The talk also covers the goals of the Catalyze program and its role in promoting the development of new therapies and entrepreneurial activities. Dr. Shapiro’ concludes with ICTR pilot grant and micro-grant opportunities as well as ICTR cores of services available to researchers.